Roberta A Diotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6153610/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Conventional and nontraditional delivery methods and routes of vaccine administration. , 2022, , 329-355.		0
2	Unconventional CD147â€dependent platelet activation elicited by SARSâ€CoVâ€2 in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2022, 20, 434-448.	3.8	50
3	Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2. Viruses, 2022, 14, 1232.	3.3	2
4	Weak correlation between antibody titers and neutralizing activity in sera from SARS oVâ€2 infected subjects. Journal of Medical Virology, 2021, 93, 2160-2167.	5.0	52
5	Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials. Emerging Microbes and Infections, 2021, 10, 206-209.	6.5	74
6	Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy. Viruses, 2021, 13, 1514.	3.3	12
7	Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection. PLoS Pathogens, 2021, 17, e1009878.	4.7	52
8	New Insights into Immune-Based Diagnosis, Therapy and Prophylaxis for Infectious Diseases 2020. Journal of Immunology Research, 2021, 2021, 1-2.	2.2	0
9	Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols. Virology Journal, 2020, 17, 103.	3.4	4
10	Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro. Frontiers in Microbiology, 2020, 11, 1704.	3.5	18
11	Editorial: Immunotherapeutic and Immunoprophylactic Strategies for Infectious Diseases. Frontiers in Immunology, 2020, 11, 1670.	4.8	3
12	Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome–Coronavirus 2 In Vitro When Administered After Virus Infection. Journal of Infectious Diseases, 2020, 222, 722-725.	4.0	61
13	Next Generation Vaccines for Infectious Diseases. Journal of Immunology Research, 2019, 2019, 1-2.	2.2	11
14	Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines. Journal of Immunology Research, 2019, 2019, 1-13.	2.2	72
15	Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects. Journal of Virology, 2019, 93, .	3.4	21
16	Autoimmune hepatitis and occult HCV infection: A prospective single-centre clinical study. Autoimmunity Reviews, 2017, 16, 323-325.	5.8	6
17	Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge. Antiviral Research, 2017, 143, 48-61.	4.1	9
18	A Biologically-validated HCV E1E2 Heterodimer Structural Model. Scientific Reports, 2017, 7, 214.	3.3	32

Roberta A Diotti

#	Article	IF	CITATIONS
19	New Insights for Immune-Based Diagnosis and Therapy for Infectious Diseases. Journal of Immunology Research, 2017, 2017, 1-2.	2.2	1
20	Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. Viruses, 2016, 8, 128.	3.3	2
21	Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut, 2016, 65, 512-523.	12.1	67
22	Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy. Antiviral Research, 2014, 108, 94-103.	4.1	13
23	JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?. Clinical and Developmental Immunology, 2013, 2013, 1-11.	3.3	16
24	Peptide-Based Vaccinology: Experimental and Computational Approaches to Target Hypervariable Viruses through the Fine Characterization of Protective Epitopes Recognized by Monoclonal Antibodies and the Identification of T-Cell-Activating Peptides. Clinical and Developmental Immunology, 2013, 2013, 1-12.	3.3	26
25	HCV Proteins and Immunoglobulin Variable Gene (IgV) Subfamilies in HCV-Induced Type II Mixed Cryoglobulinemia: A Concurrent Pathogenetic Role. Clinical and Developmental Immunology, 2012, 2012, 1-11.	3.3	15
26	Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. Antiviral Research, 2012, 96, 82-89.	4.1	27
27	Neutralization Interfering Antibodies: A "Novel―Example of Humoral Immune Dysfunction Facilitating Viral Escape?. Viruses, 2012, 4, 1731-1752.	3.3	26
28	A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments. New Microbiologica, 2012, 35, 289-94.	0.1	20
29	New therapeutic options for HCV infection in the monoclonal antibody era. New Microbiologica, 2012, 35, 387-97.	0.1	15
30	Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein. New Microbiologica, 2012, 35, 475-9.	0.1	8
31	Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology, 2010, 399, 144-152.	2.4	40
32	Hepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral Genotypes. PLoS ONE, 2009, 4, e8254.	2.5	64
33	Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). New Microbiologica, 2009, 32, 319-24.	0.1	22
34	Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. Autoimmunity Reviews, 2008, 7, 468-472.	5.8	33
35	Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein. Journal of Virology, 2008, 82, 1047-1052.	3.4	119